## Ralph A Tripp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3796262/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology, 2000, 1, 398-401.	7.0	1,482
2	Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene. Nature, 1996, 380, 630-633.	13.7	1,223
3	Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature, 1996, 382, 171-174.	13.7	1,059
4	Defective Lymphoid Development in Mice Lacking Jak3. Science, 1995, 270, 800-802.	6.0	620
5	Rapid and Sensitive Detection of Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate. Nano Letters, 2006, 6, 2630-2636.	4.5	578
6	Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. Journal of Virology, 2001, 75, 10730-10737.	1.5	447
7	Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunological Reviews, 1997, 159, 105-117.	2.8	407
8	Novel nanostructures for SERS biosensing. Nano Today, 2008, 3, 31-37.	6.2	396
9	CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology, 2001, 2, 732-738.	7.0	380
10	CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. Journal of Immunology, 1997, 159, 5197-200.	0.4	376
11	Stress alters immune function and disease resistance in chinook salmon (Oncorhynchus) Tj ETQq1 1 0.784314 r	gBT_/Overl	oc <u>k 1</u> 0 Tf 50
12	Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infectious Diseases, 2020, 6, 2099-2109.	1.8	239
13	Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2. Journal of Virology, 2009, 83, 1492-1500.	1.5	233
14	Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS). Biosensors and Bioelectronics, 2008, 24, 917-922.	5.3	221
15	Visible-Light-Activated Bactericidal Functions of Carbon "Quantum―Dots. ACS Applied Materials & Interfaces, 2016, 8, 10761-10766.	4.0	206
16	Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature, 1998, 392, 726-730.	13.7	196
17	Human Metapneumovirus: Lessons Learned over the First Decade. Clinical Microbiology Reviews, 2011, 24, 734-754.	5.7	167
18	Pathogenesis of an Infectious Mononucleosis-like Disease Induced by a Murine Î <sup>3</sup> -Herpesvirus: Role for a Viral Superantigen?. Journal of Experimental Medicine, 1997, 185, 1641-1650.	4.2	161

#	Article	IF	CITATIONS
19	Establishment and Persistence of Virus-Specific CD4+ and CD8+ T Cell Memory. Immunological Reviews, 1996, 150, 23-44.	2.8	152
20	Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. Journal of Virology, 1999, 73, 7099-7107.	1.5	145
21	Counting Single Native Biomolecules and Intact Viruses with Color-Coded Nanoparticles. Analytical Chemistry, 2006, 78, 1061-1070.	3.2	140
22	One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst, The, 2011, 136, 3083.	1.7	136
23	Cortisol mediated suppression of salmonid lymphocyte responses invitro. Developmental and Comparative Immunology, 1987, 11, 565-576.	1.0	134
24	RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy. Antimicrobial Agents and Chemotherapy, 2009, 53, 3952-3962.	1.4	133
25	Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses. Journal of Immunology, 2006, 176, 1600-1608.	0.4	127
26	Identification and classification of respiratory syncytial virus (RSV) strains by surface-enhanced Raman spectroscopy and multivariate statistical techniques. Analytical and Bioanalytical Chemistry, 2008, 390, 1551-1555.	1.9	127
27	Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and lg. Journal of Immunology, 1996, 157, 2947-52.	0.4	118
28	Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice. Journal of Infectious Diseases, 2009, 200, 439-447.	1.9	115
29	Flexible and mechanical strain resistant large area SERS active substrates. Nanoscale, 2012, 4, 3410.	2.8	112
30	Temporal loss of the activated L-selectin-low phenotype for virus-specific CD8+ memory T cells. Journal of Immunology, 1995, 154, 5870-5.	0.4	111
31	Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. Journal of Virology, 2003, 77, 9831-9844.	1.5	109
32	Recruitment and proliferation of CD8+ T cells in respiratory virus infections. Journal of Immunology, 1995, 154, 6013-21.	0.4	108
33	Human Metapneumovirus Persists in BALB/c Mice despite the Presence of Neutralizing Antibodies. Journal of Virology, 2004, 78, 14003-14011.	1.5	103
34	Label-Free Detection of Micro-RNA Hybridization Using Surface-Enhanced Raman Spectroscopy and Least-Squares Analysis. Journal of the American Chemical Society, 2012, 134, 12889-12892.	6.6	99
35	Detection and differentiation of foodborne pathogenic bacteria in mung bean sprouts using field deployable label-free SERS devices. Analyst, The, 2013, 138, 3005.	1.7	98
36	CD8+ T-cell memory to viruses. Current Opinion in Immunology, 1994, 6, 545-552.	2.4	97

#	Article	IF	CITATIONS
37	Label-free SERS detection of microRNA based on affinity for an unmodified silver nanorod array substrate. Chemical Communications, 2010, 46, 3298.	2.2	96
38	Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication <i>In Vitro</i> and <i>In Vivo</i> . Journal of Virology, 2014, 88, 10228-10243.	1.5	96
39	Characteristics of the influenza virus-specific CD8+ T cell response in mice homozygous for disruption of the H-2lAb gene. Journal of Immunology, 1995, 155, 2955-9.	0.4	96
40	Pathogenesis of Respiratory Syncytial Virus Infection. Viral Immunology, 2004, 17, 165-181.	0.6	93
41	Rapid and Sensitive Detection of Rotavirus Molecular Signatures Using Surface Enhanced Raman Spectroscopy. PLoS ONE, 2010, 5, e10222.	1.1	92
42	Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. Journal of General Virology, 2012, 93, 2346-2356.	1.3	90
43	Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse. Journal of Virology, 2000, 74, 6227-6229.	1.5	89
44	Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. Journal of Immunology, 1996, 157, 822-6.	0.4	89
45	Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination. Journal of Virology, 2011, 85, 1634-1644.	1.5	88
46	Real-Time Detection of Virus Particles and Viral Protein Expression with Two-Color Nanoparticle Probes. Journal of Virology, 2005, 79, 8625-8628.	1,5	87
47	Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients. Journal of Immunology, 2009, 183, 6338-6345.	0.4	87
48	Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice. Journal of Virology, 2010, 84, 1148-1157.	1.5	87
49	Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. Journal of Virology, 1996, 70, 1288-1291.	1.5	85
50	Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity. Frontiers in Immunology, 2019, 10, 566.	2.2	84
51	Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virology Journal, 2008, 5, 116.	1.4	83
52	The Immune Response to Human Metapneumovirus Is Associated with Aberrant Immunity and Impaired Virus Clearance in BALB/c Mice. Journal of Virology, 2005, 79, 5971-5978.	1.5	82
53	An Au/Si hetero-nanorod-based biosensor for <i>Salmonella</i> detection. Nanotechnology, 2008, 19, 155502.	1.3	82
54	The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiology, 2009, 4, 279-297.	1.0	82

#	Article	IF	CITATIONS
55	The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P. Journal of Virology, 2003, 77, 6580-6584.	1.5	81
56	The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Journal of Virology, 1996, 70, 2431-2439.	1.5	80
57	Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice. Journal of Virology, 2000, 74, 1614-1622.	1.5	77
58	Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper–1 and T Helper–2 Cytokines and CC Chemokine Messenger RNA. Journal of Infectious Diseases, 2002, 185, 1388-1394.	1.9	77
59	Fabrication and characterization of a multiwell array SERS chip with biological applications. Biosensors and Bioelectronics, 2009, 24, 3663-3670.	5.3	74
60	Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway. Viral Immunology, 2009, 22, 147-161.	0.6	73
61	Tuning into immunological dissonance: an experimental model for infectious mononucleosis. Current Opinion in Immunology, 1997, 9, 477-483.	2.4	71
62	Cytokines and Respiratory Syncytial Virus Infection. Proceedings of the American Thoracic Society, 2005, 2, 147-149.	3.5	71
63	Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1). Virology, 2011, 413, 169-182.	1.1	71
64	Cytokine production in the immune response to murine gammaherpesvirus 68. Journal of Virology, 1996, 70, 3264-3268.	1.5	71
65	Differentiation and classification of bacteria using vancomycin functionalized silver nanorods array based surface-enhanced Raman spectroscopy and chemometric analysis. Talanta, 2015, 139, 96-103.	2.9	67
66	Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice. Journal of General Virology, 2009, 90, 1119-1123.	1.3	64
67	Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Nail`ve and Formalin-Inactivated RSV-Immunized BALB/c Mice. Journal of Virology, 2010, 84, 9632-9636.	1.5	64
68	Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. Journal of Immunology, 1997, 158, 3716-20.	0.4	63
69	Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection. Journal of Interferon and Cytokine Research, 2015, 35, 554-562.	0.5	62
70	Quantitative Surface-Enhanced Raman Spectroscopy Based Analysis of MicroRNA Mixtures. Applied Spectroscopy, 2009, 63, 1107-1114.	1.2	61
71	Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology, 2007, 362, 139-150.	1.1	60
72	An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology, 2015, 483, 117-125.	1.1	60

#	Article	IF	CITATIONS
73	Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. Journal of Virology, 1993, 67, 5289-5298.	1.5	60
74	Bioconjugated nanoparticle detection of respiratory syncytial virus infection. International Journal of Nanomedicine, 2007, 2, 117-124.	3.3	59
75	Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401.	6.0	58
76	Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Review of Respiratory Medicine, 2017, 11, 609-615.	1.0	58
77	An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunology and Cell Biology, 2007, 85, 160-168.	1.0	57
78	Detection of Mycoplasma pneumoniae in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy. PLoS ONE, 2010, 5, e13633.	1.1	57
79	Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. Assay and Drug Development Technologies, 2015, 13, 638-649.	0.6	57
80	Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains. Viral Immunology, 2012, 25, 120502120244005.	0.6	56
81	Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs. PLoS ONE, 2013, 8, e66796.	1.1	55
82	Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Journal of Virology, 2018, 92, .	1.5	55
83	Respiratory Syncytial Virus (RSV) Infects Neuronal Cells and Processes That Innervate the Lung by a Process Involving RSV G Protein. Journal of Virology, 2006, 80, 537-540.	1.5	54
84	CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse. Journal of Immunology, 2000, 164, 5913-5921.	0.4	53
85	Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. Journal of Virological Methods, 2005, 128, 21-28.	1.0	53
86	A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′) <sub>2</sub> Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice. Journal of Virology, 2013, 87, 10955-10967.	1.5	53
87	Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A Virus Infection. PLoS ONE, 2013, 8, e66546.	1.1	53
88	Infectious Agent Detection With SERS-Active Silver Nanorod Arrays Prepared by Oblique Angle Deposition. IEEE Sensors Journal, 2008, 8, 863-870.	2.4	52
89	Host gene targets for novel influenza therapies elucidated by highâ€ŧhroughput RNA interference screens. FASEB Journal, 2012, 26, 1372-1386	0.2	52
90	Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. Journal of General Virology, 2013, 94, 1451-1461.	1.3	52

#	Article	IF	CITATIONS
91	The Failure of Interleukin-10–deficient Mice to Develop Airway Hyperresponsiveness Is Overcome by Respiratory Syncytial Virus Infection in Allergen–sensitized/challenged Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 824-831.	2.5	50
92	Respiratory Syncytial Virus F and G Proteins Induce Interleukin 1α, CC, and CXC Chemokine Responses by Normal Human Bronchoepithelial Cells. Journal of Infectious Diseases, 2010, 201, 1201-1207.	1.9	49
93	Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice. Journal of Virology, 2014, 88, 10569-10583.	1.5	48
94	Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. Journal of Allergy and Clinical Immunology, 2003, 112, 861-869.	1.5	46
95	Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. PLoS ONE, 2013, 8, e74905.	1.1	46
96	ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity. PLoS Biology, 2016, 14, e1002580.	2.6	46
97	Avian Influenza Viruses Infect Primary Human Bronchial Epithelial Cells Unconstrained by Sialic Acid α2,3 Residues. PLoS ONE, 2011, 6, e21183.	1.1	45
98	Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy. Antimicrobial Agents and Chemotherapy, 2013, 57, 475-483.	1.4	44
99	Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium. Journal of Virology, 2015, 89, 12309-12318.	1.5	42
100	Anti–G Protein Antibody Responses to Respiratory Syncytial Virus Infection or Vaccination Are Associated with Inhibition of G Protein CX3C X3CR1 Binding and Leukocyte Chemotaxis. Journal of Infectious Diseases, 2004, 190, 1936-1940.	1.9	41
101	Replication and pathogenesis associated with H5N1, H5N2, and H5N3 low-pathogenic avian influenza virus infection in chickens and ducks. Archives of Virology, 2009, 154, 1241-1248.	0.9	40
102	MicroRNA Regulation of Human Protease Genes Essential for Influenza Virus Replication. PLoS ONE, 2012, 7, e37169.	1.1	40
103	Virus-Vectored Influenza Virus Vaccines. Viruses, 2014, 6, 3055-3079.	1.5	40
104	Highly Sensitive and Transparent Surface Enhanced Raman Scattering Substrates Made by Active Coldly Condensed Ag Nanorod Arrays. Journal of Physical Chemistry C, 2012, 116, 20550-20557.	1.5	38
105	Immunopathology of RSV: An Updated Review. Viruses, 2021, 13, 2478.	1.5	38
106	Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. Journal of Neuroimmunology, 2002, 129, 141-153.	1.1	37
107	Detection and Differentiation of Avian Mycoplasmas by Surface-Enhanced Raman Spectroscopy Based on a Silver Nanorod Array. Applied and Environmental Microbiology, 2012, 78, 1930-1935.	1.4	37
108	Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Review of Vaccines, 2016, 15, 173-187.	2.0	37

#	Article	IF	CITATIONS
109	Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice. PLoS ONE, 2012, 7, e51485.	1.1	37
110	Visible Lightâ€Induced Photoeletrochemical and Antimicrobial Properties of Hierarchical CuBi <sub>2</sub> O <sub>4</sub> by Facile Hydrothermal Synthesis. ChemistrySelect, 2016, 1, 1518-1524.	0.7	36
111	Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Research, 2018, 154, 149-157.	1.9	36
112	Human Norovirus: Experimental Models of Infection. Viruses, 2019, 11, 151.	1.5	36
113	Nonâ€canonical autophagy functions of ATG16L1 in epithelial cells limit lethal infection by influenza A virus. EMBO Journal, 2021, 40, e105543.	3.5	36
114	Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy, 2010, 2, 655-661.	1.0	35
115	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Scientific Reports, 2016, 6, 24897.	1.6	35
116	Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game. Journal of Virology, 2016, 90, 1694-1704.	1.5	35
117	An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection. Mucosal Immunology, 2018, 11, 71-81.	2.7	35
118	Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free system. PLoS ONE, 2018, 13, e0199167.	1.1	35
119	Silver nanotriangle array based LSPR sensor for rapid coronavirus detection. Sensors and Actuators B: Chemical, 2022, 359, 131604.	4.0	35
120	Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521.	6.0	34
121	A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine, 2014, 32, 3050-3057.	1.7	34
122	Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antiviral Research, 2021, 192, 105115.	1.9	34
123	Dual Proinflammatory and Antiviral Properties of Pulmonary Eosinophils in Respiratory Syncytial Virus Vaccine-Enhanced Disease. Journal of Virology, 2015, 89, 1564-1578.	1.5	33
124	The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon. Journal of Virology, 1997, 71, 1906-1910.	1.5	33
125	Human Metapneumovirus Establishes Persistent Infection in the Lungs of Mice and Is Reactivated by Glucocorticoid Treatment. Journal of Virology, 2009, 83, 6837-6848.	1.5	32
126	Development of a Zika vaccine. Expert Review of Vaccines, 2016, 15, 1083-1085.	2.0	32

#	Article	IF	CITATIONS
127	Primary in vitro stimulation of antibody production by rainbow trout lymphocytes. Veterinary Immunology and Immunopathology, 1986, 12, 29-38.	0.5	31
128	Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection. Journal of Virology, 2002, 76, 6873-6881.	1.5	31
129	Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?. Microbes and Infection, 2006, 8, 285-293.	1.0	31
130	Animal Models for Evaluation of Influenza Vaccines. Current Topics in Microbiology and Immunology, 2009, 333, 397-412.	0.7	31
131	Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection. PLoS ONE, 2016, 11, e0167221.	1.1	31
132	Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 253-262.	1.7	30
133	MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication. PLoS ONE, 2016, 11, e0155104.	1.1	29
134	ACE2-lgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. lScience, 2022, 25, 103670.	1.9	29
135	TH1- AND TH2-TYPE CYTOKINE EXPRESSION BY ACTIVATED TLYMPHOCYTES FROM THE LUNG AND SPLEEN DURING THE INFLAMMATORY RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS. Cytokine, 2000, 12, 801-807.	1.4	28
136	Comparative Pathology in Ferrets Infected with H1N1 Influenza A Viruses Isolated from Different Hosts. Journal of Virology, 2011, 85, 7572-7581.	1.5	27
137	Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge. Viral Immunology, 2014, 27, 112-123.	0.6	27
138	Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines, 2016, 4, 45.	2.1	27
139	Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication <i>In Vitro</i> . Journal of Virology, 2019, 93, .	1.5	27
140	Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-l². Journal of General Virology, 2015, 96, 3179-3191.	1.3	27
141	CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine, 2003, 21, 2964-2979.	1.7	26
142	RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response. Journal of Virology, 2008, 82, 12221-12231.	1.5	26
143	Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Journal of Virology, 2017, 91, .	1.5	26
144	Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy. Analyst, The, 2010, 135, 3103.	1.7	25

#	Article	IF	CITATIONS
145	siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals, 2013, 6, 124-160.	1.7	25
146	The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection. Vaccines, 2017, 5, 16.	2.1	25
147	A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus <i>In Vivo</i> . Journal of Virology, 2019, 93, .	1.5	25
148	Memory T Cells Generated by Prior Exposure to Influenza Cross React with the Novel H7N9 Influenza Virus and Confer Protective Heterosubtypic Immunity. PLoS ONE, 2015, 10, e0115725.	1.1	25
149	Serum Mannose-Binding Lectin Levels are Linked with Respiratory Syncytial Virus (RSV) Disease. Journal of Clinical Immunology, 2008, 28, 166-173.	2.0	24
150	Gain-of-Function Experiments on H7N9. Science, 2013, 341, 612-613.	6.0	24
151	The Brume Surrounding Respiratory Syncytial Virus Persistence. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 778-779.	2.5	23
152	Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. Vaccines, 2015, 3, 829-849.	2.1	23
153	Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses. Viruses, 2018, 10, 48.	1.5	23
154	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro. Scientific Reports, 2021, 11, 18085.	1.6	23
155	Aerosol Inoculation with a Sub-lethal Influenza Virus Leads to Exacerbated Morbidity and Pulmonary Disease Pathogenesis. Viral Immunology, 2011, 24, 131-142.	0.6	22
156	Bat cells from <i><scp>P</scp>teropus alecto</i> are susceptible to influenza <scp>A</scp> virus infection and reassortment. Influenza and Other Respiratory Viruses, 2013, 7, 900-903.	1.5	22
157	Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs, 2014, 6, 460-473.	2.6	22
158	Development of improved vaccine cell lines against rotavirus. Scientific Data, 2017, 4, 170021.	2.4	22
159	Cytotoxic T-Lymphocyte Precursor Frequencies in BALB/c Mice after Acute Respiratory Syncytial Virus (RSV) Infection or Immunization with a Formalin-Inactivated RSV Vaccine. Journal of Virology, 1998, 72, 8971-8975.	1.5	22
160	Emerging Technologies in Nanotechnology-Based Pathogen Detection. Clinical Microbiology Newsletter, 2009, 31, 137-144.	0.4	21
161	Identification of Virulence Determinants in Influenza Viruses. Analytical Chemistry, 2014, 86, 6911-6917.	3.2	21
162	Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus. Inflammation Research, 2016, 65, 71-80.	1.6	21

#	Article	IF	CITATIONS
163	Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains. Veterinary Microbiology, 2017, 211, 174-179.	0.8	21
164	MicroRNA-555 has potent antiviral properties against poliovirus. Journal of General Virology, 2016, 97, 659-668.	1.3	21
165	Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3. Blood, 1999, 94, 1906-1914.	0.6	21
166	Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose. Vaccine, 2012, 30, 3026-3033.	1.7	20
167	Targeting Cell Division Cycle 25 Homolog B To Regulate Influenza Virus Replication. Journal of Virology, 2013, 87, 13775-13784.	1.5	20
168	Laser light suicide of proliferating virus-specific CD8+ T cells in an in vivo response. Journal of Immunology, 1995, 155, 3719-21.	0.4	19
169	Serological cross-reactivity of members of the Metapneumovirus genus. Virus Research, 2004, 105, 67-73.	1.1	18
170	Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome. Virus Research, 2017, 235, 115-120.	1.1	18
171	Tumor Progression Locus 2 Promotes Induction of IFNλ, Interferon Stimulated Genes and Antigen-Specific CD8+ T Cell Responses and Protects against Influenza Virus. PLoS Pathogens, 2015, 11, e1005038.	2.1	18
172	Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine, 2004, 22, 2248-2260.	1.7	17
173	Adenovirus 36, adiposity, and bone strength in late-adolescent females. Journal of Bone and Mineral Research, 2013, 28, 489-496.	3.1	17
174	Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice. PLoS ONE, 2013, 8, e83075.	1.1	17
175	Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies. Viruses, 2021, 13, 352.	1.5	17
176	Modification of the Sendai virus-specific antibody and CD8+ T-cell responses in mice homozygous for disruption of the interleukin-4 gene. Journal of Virology, 1997, 71, 2518-2521.	1.5	17
177	Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine, 2011, 29, 2568-2575.	1.7	16
178	Antiviral Responses by Swine Primary Bronchoepithelial Cells Are Limited Compared to Human Bronchoepithelial Cells Following Influenza Virus Infection. PLoS ONE, 2013, 8, e70251.	1.1	16
179	Dual oxidase 1 promotes antiviral innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
180	A universal mammalian vaccine cell line substrate. PLoS ONE, 2017, 12, e0188333.	1.1	16

#	Article	IF	CITATIONS
181	CD4+ T Cell Frequencies and Th1/Th2 Cytokine Patterns Expressed in the Acute and Memory Response to Respiratory Syncytial Virus I-Ed-Restricted Peptides. Cellular Immunology, 2001, 207, 59-71.	1.4	15
182	Molecular and cellular mechanisms in the viral exacerbation of asthma. Microbes and Infection, 2008, 10, 1014-1023.	1.0	15
183	Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Frontiers in Immunology, 2019, 10, 2323.	2.2	15
184	Innate and adaptive immune responses in respiratory virus infection: implications for the clinic. Expert Review of Respiratory Medicine, 2020, 14, 1141-1147.	1.0	15
185	Antiviral cytotoxic activity across a species barrier in mixed xenogeneic chimeras: functional restriction to host MHC. Journal of Immunology, 1998, 160, 3790-6.	0.4	15
186	Advances in and the potential of vaccines for respiratory syncytial virus. Expert Review of Respiratory Medicine, 2013, 7, 411-427.	1.0	14
187	Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection. Journal of Leukocyte Biology, 2014, 96, 447-452.	1.5	14
188	MicroRNA screening identifies miR-134 as a regulator of poliovirus and enterovirus 71 infection. Scientific Data, 2017, 4, 170023.	2.4	14
189	Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opinion on Investigational Drugs, 2020, 29, 285-294.	1.9	14
190	Passage of low-pathogenic avian influenza (LPAI) viruses mediates rapid genetic adaptation of a wild-bird isolate in poultry. Archives of Virology, 2011, 156, 565-576.	0.9	13
191	Antiviral Effects of Inhibiting Host Gene Expression. Current Topics in Microbiology and Immunology, 2014, 386, 459-477.	0.7	13
192	Therapeutic Applications of RNAi for Silencing Virus Replication. Methods in Molecular Biology, 2009, 555, 43-61.	0.4	13
193	Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opinion on Investigational Drugs, 2022, 31, 23-29.	1.9	13
194	Human Respiratory Syncytial Virus: An Introduction. Methods in Molecular Biology, 2016, 1442, 1-12.	0.4	12
195	Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
196	Gene-edited vero cells as rotavirus vaccine substrates. Vaccine: X, 2019, 3, 100045.	0.9	12
197	Original Antigenic Sin and Respiratory Syncytial Virus Vaccines. Vaccines, 2019, 7, 107.	2.1	12
198	Losartan Inhibits SARS-CoV-2 Replication in Vitro. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 390-399.	0.9	12

#	Article	IF	CITATIONS
199	Targeting the proâ€inflammatory factor CCL2 (MCPâ€1) with Bindarit for influenza A (H7N9) treatment. Clinical and Translational Immunology, 2017, 6, e135.	1.7	11
200	A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Virology, 2017, 509, 60-66.	1.1	11
201	Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opinion on Biological Therapy, 2020, 20, 1073-1082.	1.4	11
202	Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein. Journal of Virology, 2021, 95, e0059321.	1.5	11
203	Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs. PLoS ONE, 2021, 16, e0257563.	1.1	11
204	Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3. Blood, 1999, 94, 1906-1914.	0.6	11
205	G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication. Journal of Virology, 2021, 95, .	1.5	10
206	Recombinant vaccines for influenza virus. Current Opinion in Investigational Drugs, 2008, 9, 836-45.	2.3	10
207	Vero Cells as a Mammalian Cell Substrate for Human Norovirus. Viruses, 2020, 12, 439.	1.5	9
208	A Novel Influenza Virus Hemagglutinin-Respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine against Influenza and RSV. Journal of Virology, 2013, 87, 10792-10804.	1.5	8
209	Gammaherpesvirus infection modulates the temporal and spatial expression of SCGB1A1 (CCSP) and BPIFA1 (SPLUNC1) in the respiratory tract. Laboratory Investigation, 2015, 95, 610-624.	1.7	8
210	Exosome-mediated human norovirus infection. PLoS ONE, 2020, 15, e0237044.	1.1	8
211	Host Gene Expression and Respiratory Syncytial Virus Infection. Current Topics in Microbiology and Immunology, 2013, 372, 193-209.	0.7	8
212	Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses, 2022, 14, 912.	1.5	8
213	Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
214	Surveillance of feral cats for influenza A virus in North Central Florida. Influenza and Other Respiratory Viruses, 2012, 6, 341-347.	1.5	7
215	Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis. Immune Network, 2013, 13, 163.	1.6	7
216	Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression. Journal of Virology, 2015, 89, 5651-5667.	1.5	7

#	Article	IF	CITATIONS
217	Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay. Methods in Molecular Biology, 2016, 1442, 33-40.	0.4	7
218	Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system. Scientific Reports, 2019, 9, 366.	1.6	7
219	Polymerase Discordance in Novel Swine Influenza H3N2v Constellations Is Tolerated in Swine but Not Human Respiratory Epithelial Cells. PLoS ONE, 2014, 9, e110264.	1.1	7
220	The use of a handheld Raman system for virus detection. Proceedings of SPIE, 2012, , .	0.8	6
221	Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy. Analyst, The, 2015, 140, 7748-7760.	1.7	6
222	Molecular epidemiology and glycomics of swine influenza viruses circulating in commercial swine farms in the southeastern and midwest United States. Veterinary Microbiology, 2020, 251, 108914.	0.8	6
223	Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication. Scientific Reports, 2021, 11, 19223.	1.6	6
224	Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses. ACS Infectious Diseases, 2022, 8, 596-611.	1.8	6
225	Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication. Viruses, 2022, 14, 612.	1.5	6
226	Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection. Current Pharmaceutical Design, 2003, 9, 51-59.	0.9	5
227	Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host. Archives of Virology, 2015, 160, 2455-2470.	0.9	5
228	MicroRNA and Nonsense Transcripts as Putative Viral Evasion Mechanisms. Frontiers in Cellular and Infection Microbiology, 2019, 9, 152.	1.8	5
229	Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses, 2021, 13, 625.	1.5	5
230	Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood, 1999, 94, 1906-14.	0.6	5
231	Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs. BioTechniques, 2022, 72, 263-272.	0.8	5
232	Modeling Respiratory Syncytial Virus Cytopathogenesis in the Human Airway. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 766-767.	2.5	4
233	Zinc affects miR-548n, SMAD4, SMAD5 expression in HepG2 hepatocyte and HEp-2 lung cell lines. BioMetals, 2015, 28, 959-966.	1.8	4
234	MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples. Methods in Molecular Biology, 2016, 1442, 195-208.	0.4	4

#	Article	IF	CITATIONS
235	Detection of swine influenza virus in nasal specimens by reverse transcription-loop-mediated isothermal amplification (RT-LAMP). Journal of Virological Methods, 2021, 288, 114015.	1.0	4
236	Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro. PLoS ONE, 2021, 16, e0259129.	1.1	4
237	The Hypothiocyanite and Amantadine Combination Treatment Prevents Lethal Influenza A Virus Infection in Mice. Frontiers in Immunology, 2022, 13, .	2.2	4
238	Current Progress on Surface-Enhanced Raman Scattering Chemical/Biological Sensing. ACS Symposium Series, 2012, , 235-272.	0.5	3
239	Virologic Differences Do Not Fully Explain the Diversification of Swine Influenza Viruses in the United States. Journal of Virology, 2016, 90, 10074-10082.	1.5	3
240	MicroRNA-134 regulates poliovirus replication by IRES targeting. Scientific Reports, 2017, 7, 12664.	1.6	3
241	Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1. Journal of Virology, 2020, 94, .	1.5	3
242	Innate Antiviral Cytokine Response to Swine Influenza Virus by Swine Respiratory Epithelial Cells. Journal of Virology, 2021, 95, e0069221.	1.5	3
243	Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice. Journal of General Virology, 2013, 94, 1701-1711.	1.3	2
244	Evasion of Host Immune Responses by Tumours and Viruses. Novartis Foundation Symposium, 1994, 187, 245-270.	1.2	2
245	Advances in Vaccine Development. Vaccines, 2021, 9, 1036.	2.1	1
246	A pioneering countermeasure against measles virus. Annals of Translational Medicine, 2015, 3, S15.	0.7	1
247	Influenza Virus (Orthomyxovirus), Infection and Immunity. , 1998, , 1385-1387.		0
248	Revised model for early memory T-cell protection against respiratory virus challenge. Future Virology, 2008, 3, 533-536.	0.9	0
249	Can an influenza A-based delivery system overcome current challenges associated with miRNA technology?. Future Virology, 2014, 9, 879-882.	0.9	0
250	Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus). Lab Animal, 2016, 45, 333-337.	0.2	0
251	Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection. Current Topics in Microbiology and Immunology, 2017, 419, 215-241.	0.7	0
252	Viral Modulation of Host Translation and Implications for Vaccine Development. , 2018, , .		0

#	Article	IF	CITATIONS
253	Editorial: Understanding the Limitations of Current Influenza Vaccine Strategies and Future Development of More Efficacious Preventative and Therapeutic Interventions. Frontiers in Immunology, 2019, 10, 2804.	2.2	0
254	Pathobiology of Respiratory Syncytial Virus (RSV). Vaccines, 2020, 8, 367.	2.1	0
255	Peter C. Doherty: A Legacy of Mentoring. Viral Immunology, 2020, 33, 143-144.	0.6	0
256	Small Non-coding RNA Expression Following Respiratory Syncytial Virus or Measles Virus Infection of Neuronal Cells. Frontiers in Microbiology, 2021, 12, 671852.	1.5	0
257	Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics. , 2012, , 5382-5398.		0
258	Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics. , 2013, , 147-169.		0
259	Therapeutic Considerations for Middle East Respiratory Syndrome Coronavirus. Journal of Antivirals & Antiretrovirals, 2013, 05, .	0.1	0
260	MicroRNAs affect GPCR and Ion channel genes needed for influenza replication. Journal of General Virology, 2021, 102, .	1.3	0